Sotera Health share price today

Sotera Health Company's share price was $16.39 at the close on 4 November 2026. It has been moving sideways for 1 week. That is 3.4% below its average price over the last 200 trading days. In the last 52 weeks it traded between $13 and $20, and at that close it sat 51% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Sotera Health Company is in stage 1. The phase helps read everything below.

Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running.

Over the last 5.9 years the share price moved −41% while the S&P 500 moved +111%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Sotera Health Company pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Sotera Health is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Sotera Health Company earned $53.6 M of net profit in the Jun 2026 quarter, +573.8% on the same quarter a year earlier. Full-year FY25 profit was $77.9 M. Over 4 years profit has grown −9.3% a year on average. That is 16.7% of the quarter's revenue. The same quarter a year earlier earned $8.0 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

2 of the last 12 reported quarters were loss-making.

For the full year, FY25 profit was $77.9 M (+75.8% on the year before).

Why profit moved: revenue changed +9.2% on a year earlier and the margin moved +2.7 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +313.9% and revenue +8.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit.

Sotera Health Company reported $321 M of revenue in the Jun 2026 quarter, +9.2% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 4 years it has grown 5.7% a year on average. The last full year, FY25, came in at $1.2 B.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to $1.2 B.

Recent pace: the last four quarters grew +8.2% on average, against 5.7% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +8.1%, against +5.2% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +581.0%, against +102.5% a year (accelerating).

Sotera Health Company's operating margin was 38.0% in the Jun 2026 quarter, 2.7 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 30.5% and 35.6%. The latest quarter is above every full year in that period.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Across 5 years it has been between 30.5% and 35.6%, and FY25's 35.6% is the highest of them.

Why the margin moved: operating margin changed +2.7 percentage points on the year while gross margin changed −1.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

As noted under valuation: when margins are at a record, every ratio built on profit looks better than usual, so a low multiple can mislead.

Over the last 3 years, 210% of Sotera Health Company's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $287 M of operating cash against $77.9 M of profit. After $138 M of spending on assets, $149 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Sotera Health Company does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $532 M on assets over the last 3 years. Averaged over those years that is 15.2% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $532 M over the last 3 years.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Sotera Health Company's P/E is 27.3×, near the low end of its own history: it has been lower only 8% of the time. Its usual P/E (the middle reading) is 59.0×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

Keep one thing in mind: margins are the best this company has ever reported. A multiple that looks low against its own past can mislead when profit is at a record. If margins fall back, today's multiple is higher than it looks.

Why the multiple is where it is: over the past year earnings per share moved +72.2% while the price moved +4.5%. Earnings did better than the price, which pulled the multiple down within its own range.

Where the price move came from: over 3 years the price moved +7.5% a year; about +47.4% a year came from earnings growth and about −39.9 percentage points from the multiple (the market paying less). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple.

Sotera Health Company's business is giving mixed signals. There is no clear direction across the growth lines, with ROCE steady at 12.5%; each line tells part of the story. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: when the lines disagree, each line above matters more than any single label.

The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Sotera Health Company earned a ROE of 13% in FY25. That is up from a low of −67% in FY22. Its return on capital used (ROIC) is 0.0 percentage points above its cost of capital, so growth here does not yet pay for the capital it uses.

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

It comes from a 6.7% net margin and 0.36× asset turnover (sales divided by assets).

Why the return is what it is (FY25): a 6.7% net margin × 0.36× asset turnover × 5.38× leverage (assets divided by equity) ≈ 13.0% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: 11.0% − 11.0% = +0.0 percentage points. The 11.0% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The 11.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 8.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Sotera Health Company has total debt of $2.3 B against shareholder equity of $666 M as of Jun 2026, so its debt is 3.41× its equity. Year by year, that ratio went from 3.12 in FY21 to 3.76 in FY25. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

8.0% of Sotera Health Company's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 7.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

For Sotera Health Company, the Z-score is 1.89. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 1.89 is in the grey area, neither clearly safe nor clearly in trouble.

51.3 out of 100, rank 12 of 30 in Diagnostics & Research, with 71% of the evidence available.

Sotera Health Company scores 51.3 out of 100 against the 30 companies it is compared with in Diagnostics & Research, ranking 12. Earnings are strong; relative strength in its sector is -32.4% and the one-year return is 4.5%.

The four parts add up to the total exactly: 23.6 + 17 + 9.8 + 0.9 = 51.3. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Sotera Health ranks 12 of 30 Diagnostics & Research companies on the 4-Factor Sector Score, with 51.3 out of 100.